Precede Biosciences

Thank you Tal Behar and the team at #PMWC25 for organizing another successful event this year focused on the ideas and innovations in precision medicine. We are grateful to have been part of it and wanted to thank all who attended Precede Biosciences' company showcase today from J.Carl Barrett. #LiquidBiopsy #DrugDevelopment #PrecisionMedicine

Check out the latest Q&A interview between Juilee Malavade, Ph.D. from DeciBio and Rehan Verjee, Precede Biosciences' co-founder and CEO. #LiquidBiopsy #Epigenomics #PrecisionMedicine #DrugDevelopment

Precede Biosciences is excited to participate in the upcoming PMWC - Precision Medicine World Conference taking place February 5-7, 2025 in Santa Clara, California. #PMWC2025 is the premier forum for leaders transforming the future of healthcare. Our team members - Chief Scientific Officer, J.Carl Barrett, PhD and our VP of Corporate and Business Development, Josephine N. Harada, PhD - will be in Santa Clara for #PMWC25 next week. If you're attending, meet the team to learn how our platform will impact precision medicine. And, check out our company showcase: "Comprehensive Epigenomic Profiling from Plasma to Inform Therapy Selection" https://bit.ly/4gfsYpB #LiquidBiopsy #PMWC25 Tal Behar

We're excited to announce a new team member, Sunny Das, PhD, has joined Precede Biosciences as Senior Scientist, Translational Sciences. #WelcomeAboard #MeetOurTeam

We're excited to announce a new team member, Patrick Brosnan, has joined Precede Biosciences?as Director, Strategy & Operations. #WelcomeAboard #MeetOurTeam

We're excited to announce a new team member, Daniel Karl, PhD, has joined Precede Biosciences as Director, Translational Sciences. #WelcomeAboard #MeetOurTeam

Winship medical oncologist Jacob E. Berchuck, MD recently spoke with Targeted Oncology on how a new epigenomic platform may influence the accessibility of prostate-specific membrane antigen (PSMA)-based therapies, especially for patients who may not have easy access to PSMA PET scans. Learn more ?? https://brnw.ch/21wPMdg

Unveiling AI’s Transformative Role in #ProstateCancerCare #PMWC25 AI is redefining prostate cancer diagnostics and treatment, driving a new era of precision medicine. From?multimodal AI (#MMAI)?algorithms included in the #NCCN Guidelines to cutting-edge imaging tools like?#PSMA #PET, the integration of AI is revolutionizing how we understand and treat this disease. Dr. William Oh, prominent prostate oncologist, Yale Cancer Center's PM Director and Chair of?PMWC 2025’s AI Models for RWE/D Applications?session, shares some exciting advancements: Personalized Treatment with AI:?Multimodal AI is now helping risk stratify localized prostate #cancerpatients and determine who benefits most from #hormonetherapy alongside #radiation. The Genomics-AI Connection:?As sequencing costs decrease, the fusion of genomics and AI will unlock patterns for truly individualized cancer care. Revolutionary Imaging:?AI enhances tools like PSMA PET, allowing #clinicians to quantify disease intensity and guide #radioligand #therapy decisions. ?Dr. Oh also highlights?AI-driven drug discovery, where real-world evidence and in silico chemistry are uncovering combinations of therapies unimaginable just a few years ago. These groundbreaking innovations are at the heart of PMWC 2025’s Track 2, which will explore how AI can harness real-world evidence to revolutionize healthcare outcomes. And that’s just the beginning. PMWC 2025 features a diverse array of sessions, including: “AI in Radiology and Imaging Applications”?(Paul Chang, University of Chicago; Curtis Langlotz; Sharmila Majumdar; Eliot Siegel, VA Maryland Healthcare System; Katherine Andriole, Brigham and Women's Hospital) "How to Implement AI for Faster Readout of Clinical Trials”?(Jennifer Webster, Pfizer; Brandon Allgood, Parabilis Medicines; Julian Hong, UCSF; Andrew Roddam, EveryONE Medicines; Michiel JM Niesen, nference) “Leveraging AI and Real-World Evidence to Transform Patient Care”?(Amrita Basu, UCSF) “Radiopharmaceuticals for Cancer Therapy”?(William Oh, Naga Vara Kishore Pillarsetty, Memorial Sloan Kettering; Jones Nauseef, Convergent Therapeutics, Inc.; Thomas Hope, University of California, San Francisco) “Advancements in Digital Imaging: Enhancing Accuracy in Cancer Diagnostics”?(Razelle Kurzrock, Medical College of Wisconsin; Hedvig (Hedi) Hricak; Wafik S. El-Deiry, MD, PhD, FACP, Brown University/WIN) Showcase: J.Carl Barrett (Precede Biosciences): Advancing liquid biopsy innovations for diagnostics. Join Us:?Explore these innovations and more at?PMWC 2025?(Feb 5-7, Santa Clara Convention Center with 2500 attendees. PMWC 2025 Program: https://lnkd.in/gPtkWZbQ Exact Sciences, Tempus AI, Promaxo, ArteraAI PMWC - Precision Medicine World Conference, Tomasz (Tom) Beer, Eric A. Klein, MD, Dan McCormick, Stacy Loeb, Matt Cooperberg #PMWC25 #PrecisionMedicine #ArtificialIntelligence #ProstateCancer #RealWorldEvidence #CancerDiagnostics #Radiopharmaceuticals #ClinicalTrials #DigitalImaging

?? Exciting progress from our portfolio company, Precede Biosciences! At SABCS 2024, Precede presented their novel ER Transcriptional Dependency Index (PERDI), a blood-based test designed to enhance the use of endocrine therapy in ER+ metastatic #BreastCancer.? ?? This innovative approach addresses critical unmet needs in treatment decision-making, with the potential to identify patients who might benefit from monotherapy with emerging oral selective estrogen receptor degraders (SERDs) and antibody-drug conjugates (ADCs).? ? Learn more about Precede’s impactful work here: https://lnkd.in/dNjPqyYK? ? #PartnerNews?

Thank you to everyone who stopped by our #SABCS24 poster spotlight presentation with Precede Biosciences' Jonathan Beagan today. We love sharing our science and appreciate the interest in scientific exchange. #LiquidBiopsy #BreastCancer #DrugDevelopment